Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 9/20 | 0.58 |
| ▸ | HPGDS | O60760 | 1/20 | 0.54 |
| ▸ | GLS | O94925 | 3/20 | 0.52 |
| ▸ | SMO | Q99835 | 1/20 | 0.51 |
| ▸ | HTR1D | P28221 | 1/20 | 0.51 |
| ▸ | HTR1B | P28222 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | BRAF | P15056 | 1/20 | 0.51 |
| ▸ | CSF1R | P07333 | 1/20 | 0.48 |
| ▸ | KIT | P10721 | 1/20 | 0.48 |
| ▸ | BTK | Q06187 | 2/20 | 0.48 |
| ▸ | HCK | P08631 | 1/20 | 0.48 |
| ▸ | NR2C2 | P49116 | 1/20 | 0.48 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2972329 | 0.97 | MAPK14 (0.61) | MAPK14HPGDSGLSSMOHTR1D | |
| SCHEMBL7855875 | 0.93 | MAPK14 (0.52) | MAPK14GLSHTR1DHTR1BHTR2A | |
| SCHEMBL6782251 | 0.91 | MAPK14 (0.66) | MAPK14HPGDSGLSSMOBRAF | |
| SCHEMBL27581172 | 0.90 | MAPK14 (0.58) | MAPK14HPGDSSMOBRAFCSF1R | |
| SCHEMBL7846789 | 0.90 | MAPK14 (0.55) | MAPK14HPGDSGLSHTR1DHTR1B | |
| SCHEMBL7779426 | 0.90 | MAPK14 (0.58) | MAPK14HPGDSGLSSMOBRAF | |
| SCHEMBL6980722 | 0.85 | MAPK14 (0.65) | MAPK14HPGDSBRAF | |
| SCHEMBL2979099 | 0.84 | MAPK14 (0.65) | MAPK14SMOBRAFCSF1RBTK | |
| SCHEMBL6968243 | 0.81 | MAPK14 (0.61) | MAPK14HPGDSBRAF | |
| SCHEMBL6979954 | 0.80 | HPGDS (0.61) | MAPK14HPGDSSMOBRAFCSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6821965-B1 | IMPORTANT IN DISEASE OR MEDICAL CONDITIONS SUCH AS INFLAMMATION AND IMMUNOREGULATION | ASTERZENECA AB (SE) | 2004-11-23 | — | — | US | claimed |
| US-7772432-B2 | Amidobenzamide derivatives which are useful as cytokine inhibitors | ASTRAZENECA AB (SE) | 2010-08-10 | — | — | US | disclosed |
| US-20050038081-A1 | Amidobenzamide derivatives which are useful as cytokine inhibitors | ASTRAZENECA | 2005-02-17 | — | — | US | disclosed |
| US-6821965-B1 | IMPORTANT IN DISEASE OR MEDICAL CONDITIONS SUCH AS INFLAMMATION AND IMMUNOREGULATION | ASTERZENECA AB (SE) | 2004-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038081-A1 | Amidobenzamide derivatives which are useful as cytokine inhibitors | IL6, IL6ST, IL2 | MAPK14 1775/4885HPGDS 855/4885GLS 1242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.